Welcome to SN Connect, the medical oncology education platform from SurvivorNet.

Sign Up

Practice Changing Developments: Unique Perspectives

Read4 MIN READ
FDA Clears First‑in‑Class Oral Therapy-- CELMoD ZENBEXUS for Previously Treated Multiple Myeloma Patients-- Potentially Helpful for Community Practices
Read5 MIN READ
Melanoma Vaccine Breakthrough: Phase 3 Trial Shows Strong Protection Against Recurrence and Spread
Read4 MIN READ
After INDIGO’s Strong Results, Experts Say the Future of IDH Inhibition Hinges on Timing, Quality of Life, and Smarter Strategies
Read5 MIN READ
ASCO Updates: SUCCESSOR-2 Explores a New Sequencing Strategy After Lenalidomide in Multiple Myeloma
Read8 MIN READ
VIKTORIA-1 May Sharpen Post-CDK4/6 Choices in PIK3CA-Mutant HR+ Breast Cancer
Read7 MIN READ
Daraxonrasib at ASCO 2026: Phase 3 RASolute 302 Data Arrive, And the Second-Line Paradigm in Metastatic PDAC May Never Look the Same
Read9 MIN READ
PROTEUS Final Analysis at ASCO 2026: Perioperative Apalutamide Delivers And The Localized High-Risk Paradigm Shifts
Read5 MIN READ
persevERA Breast Cancer Study Keeps Oral ER-Targeting Strategy in Focus Despite Negative Primary Result
Read9 MIN READ
ASCO 2026: A Bispecific Antibody Just Cracked One of Lung Cancer's Hardest Problems - OS Data Are In, But The U.S. Question Isn't Answered Yet
Read3 MIN READ
MHQ: Clinical Intelligence--AI Powering Faster, Smarter Clinical Decisions
Read2 MIN READ
For High-Grade Glioma, Targeted BRAF Inhibitor Plixorafenib Granted FDA Breakthrough Status After Promising Early Trials
Read4 MIN READ
From ‘Undruggable’ To Actionable: RAS Inhibitors & A Potential New Era Of Targeted Therapy For Pancreatic Cancer
Read7 MIN READ
Expanding the Role of PSMA-Targeted Radioligand Therapy in Prostate Cancer: Early Insights From PSMA Addition and the Evolving Use of Lutetium-177–PSMA (Pluvicto)
Read4 MIN READ
LIDERA: The First Oral SERD to Demonstrate a Disease-Free Survival Benefit in Early-Stage HR+ Breast Cancer
Read7 MIN READ
The AKT Inhibitor Has Arrived: CAPItello-281 Data Are Practice-Changing for PTEN-Deficient Metastatic Prostate Cancer
FDA Clears First‑in‑Class Oral Therapy-- CELMoD ZENBEXUS for Previously Treated Multiple Myeloma Patients-- Potentially Helpful for Community Practices
Melanoma Vaccine Breakthrough: Phase 3 Trial Shows Strong Protection Against Recurrence and Spread
After INDIGO’s Strong Results, Experts Say the Future of IDH Inhibition Hinges on Timing, Quality of Life, and Smarter Strategies
ASCO Updates: SUCCESSOR-2 Explores a New Sequencing Strategy After Lenalidomide in Multiple Myeloma
VIKTORIA-1 May Sharpen Post-CDK4/6 Choices in PIK3CA-Mutant HR+ Breast Cancer
Daraxonrasib at ASCO 2026: Phase 3 RASolute 302 Data Arrive, And the Second-Line Paradigm in Metastatic PDAC May Never Look the Same
abstract design
PROTEUS Final Analysis at ASCO 2026: Perioperative Apalutamide Delivers And The Localized High-Risk Paradigm Shifts
persevERA Breast Cancer Study Keeps Oral ER-Targeting Strategy in Focus Despite Negative Primary Result
ASCO 2026: A Bispecific Antibody Just Cracked One of Lung Cancer's Hardest Problems - OS Data Are In, But The U.S. Question Isn't Answered Yet
MHQ: Clinical Intelligence--AI Powering Faster, Smarter Clinical Decisions
For High-Grade Glioma, Targeted BRAF Inhibitor Plixorafenib Granted FDA Breakthrough Status After Promising Early Trials
From ‘Undruggable’ To Actionable: RAS Inhibitors & A Potential New Era Of Targeted Therapy For Pancreatic Cancer
Expanding the Role of PSMA-Targeted Radioligand Therapy in Prostate Cancer: Early Insights From PSMA Addition and the Evolving Use of Lutetium-177–PSMA (Pluvicto)
LIDERA: The First Oral SERD to Demonstrate a Disease-Free Survival Benefit in Early-Stage HR+ Breast Cancer
The AKT Inhibitor Has Arrived: CAPItello-281 Data Are Practice-Changing for PTEN-Deficient Metastatic Prostate Cancer

ASCO 2026: Late Breaking Developments

Breast Cancer: Practice Changing Developments

Blood Cancers: Practice Changing Developments

Radiation Oncology: Practice Changing Developments

Get The Support You Need

See All News

Insights & Perspectives

Clinical Updates

For HR+/HER2- Early-Stage Breast Cancer at Increased Risk of Recurrence, Kisqali Has Benefits: Study
A Powerful Tool: Integrating Venetoclax into CLL Management Improves Survival
Oncologists Weigh in on Optimal Use of CDK 4/6 Inhibitors as Adjuvant Therapy in Early Breast Cancer
Imfinzi Improves Overall & Progression-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer
Balversa's FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer
Unprecedented Progression-Free Survival for ALK-Positive Non-Small Cell Lung Cancer Using Lorbrena — What the New Research Means for Patients
Physicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval
For Women With Heavily-Treated Triple-Negative or HR+, HER2- Metastatic Breast Cancer, Enfortumab Vedotin (Padcev) Shows Some Anti-Tumor Activity
Understanding Pluvicto (Lutetium-177) and PSMA PET Scans in Prostate Cancer Treatment
Elahere for Ovarian Cancer: Prevention, Detection & Management of Ocular Adverse Events

Patient Care Updates

Why Physicians Should Prioritize Emotional Wellbeing

The issue of burnout has long plagued physicians given the many hours of physically and mentally draining work. But with the recent Covid pandemic and the resulting changes to the industry, the demands on doctors is even higher — and many may be experiencing profession-related mental health issues.

Now more than ever, it’s important to pay attention to the idea of compassion fatigue, says Dr. Marianna Strongin, a licensed clinical psychologist and founder of Strong in Therapy, her Manhattan-based private practice.

Addressing Disparities

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider